{
    "brief_title": "Pyrotinib in Combination With Letrozole in Patients With HER2-Positive, ER-Positive Metastatic Breast Cancer",
    "phase": "Phase 2",
    "drugs": "['Pyrotinib Maleate plus Letrozole']",
    "drugs_list": [
        "Pyrotinib Maleate plus Letrozole"
    ],
    "diseases": "['Metastatic Breast Cancer']",
    "diseases_list": [
        "Metastatic Breast Cancer"
    ],
    "enrollment": "86.0",
    "inclusion_criteria": "inclusion criteria: \n\n Patients with HER2+/ER+ recurrent or metastatic breast cancer confirmed by histopathology; \n\n HER2 positive: HER2 IHC 3+, or HER2 IHC 2+ and ISH positive \n\n ER positive: the percentage of cells positive for ER expression \u2265 10% \n\n Premenopausal, perimenopausal or postmenopausal patients (with OFS, if pre- or perimenopausal); \n\n If the patient is bilateral breast cancer, metastasis lesions must be HER2 and ER positive; \n\n 18-70 years old; \n\n ECOG PS 0\uff5e1; \n\n Life expectancy is not less than 12 weeks; \n\n At least one measurable lesion according to RECIST 1.1; \n\n Prior (neo) adjuvant trastuzumab, pertuzumab or chemotherapy were eligible, and the disease free interval must be greater than 12 months from completion of (neo) adjuvant trastuzumab and pertuzumab to metastatic diagnosis; \n\n Prior (neo) adjuvant hormone therapy was allowed, if received adjuvant AI, the disease free interval must be greater than 12 months from the completion of treatment; \n\n Disease-free Survival after surgery (DFS) \u226512 months; \n\n Patients with adequate organ function before enrollment: ANC \u2265 1.5\u00d7109/L, PLT \u2265 75\u00d7109/L, Hb \u2265 100 g/L; TBIL\u22641.0ULN\uff1bALT and AST\u22643\u00d7ULN (ALT and AST\u22645\u00d7ULN if liver metastasis); BUN and Cr\u22641.5\u00d7ULN and CCr\u226550 mL/min; LVEF \u2265 50% and QTc < 480 ms; \n\n Signed informed consent. \n\n ",
    "exclusion_criteria": ": \n\n Central nervous system metastasis; \n\n patients with Visceral crisis; \n\n Unable to swallow, chronic diarrhea and intestinal obstruction, there are many factors affecting drug use and absorption; \n\n received radiotherapy, hormone therapy, chemotherapy, surgery (excluding local puncture) or molecular targeted therapy for advanced or metastatic disease; \n\n received radiotherapy, chemotherapy, surgery (excluding local puncture) or molecular targeted therapy within 4 weeks prior to randomization; \n\n Received hormone therapy within 2 weeks prior to randomization; \n\n Participated in other clinical trial within 4 weeks prior to randomization; \n\n Previous or ongoing use of HER2-targeted tyrosine kinase inhibitors (lapatinib, neratinib or pyrotinib); \n\n Other malignancies within 5 years, except for cured skin basal cell carcinoma,carcinoma in-situ of uterine cervix and squamous-cell carcinoma; \n\n Receive other anti-tumour therapy at the same time; \n\n History of immunodeficiency, including HIV positive, HCV, active hepatitis B, or other acquired, congenital immunodeficiency disorders, or organ transplantation, is known; \n\n History of any kind of Heart disease; \n\n All female patients in pregnancy or breastfeeding period, fertile women with positive baseline pregnancy tests; \n\n Evidence of significant medical illness that will substantially increase the risk on the participation or completion of the study in the investigator's judgment. Examples included, but not limited to, hypertension, severe diabetes, etc; \n\n History of neurological or psychiatric disorders, including epilepsy or dementia; \n\n Patients not eligible for this study judged by the investigator.",
    "brief_summary": "This is a prospective, single-arm, multi-center clinical study of pyrotinib in combination With letrozole in patients With HER2-Positive, ER-Positive metastatic breast cancer. Our aim was to explore the efficacy and safety of pyrotinib combined with letrozole in patients with HER2-positive, ER-positive metastatic breast cancer.",
    "NCT_ID": "NCT04407988"
}